| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Christopher Alvarez-Breckenridge | |
| Abhik Ray Chaudhury | |||
| Balveen Kaur | |||
| Amy Haseley | |||
| P2860 | cites work | Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy | Q24679781 |
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival | Q30954768 | ||
| Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor | Q33112683 | ||
| Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. | Q33320604 | ||
| Matrix metalloproteinases: a tail of a frog that became a prince | Q33337157 | ||
| Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses | Q33773376 | ||
| Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma | Q33905047 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study | Q34124333 | ||
| VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents | Q34273164 | ||
| Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. | Q34288445 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1 | Q34302130 | ||
| Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency | Q34343078 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. | Q34928710 | ||
| Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses | Q35036505 | ||
| Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells | Q35131235 | ||
| Genetic pathways to primary and secondary glioblastoma | Q35757144 | ||
| Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. | Q35945465 | ||
| Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits | Q36315458 | ||
| Conditionally replicative adenoviral vectors for malignant glioma. | Q36370081 | ||
| Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4 | Q36488714 | ||
| Gene therapeutics: the future of brain tumor therapy? | Q36532106 | ||
| ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures | Q36618750 | ||
| Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress | Q36720873 | ||
| Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant | Q36826076 | ||
| Reovirus and tumor oncolysis. | Q36873392 | ||
| A FADD-dependent innate immune mechanism in mammalian cells | Q38334155 | ||
| Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models | Q39971666 | ||
| Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy | Q40043828 | ||
| Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus | Q40050687 | ||
| Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death | Q40082305 | ||
| Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice | Q40136491 | ||
| A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus | Q40176322 | ||
| VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. | Q40181533 | ||
| Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model | Q40181544 | ||
| Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide | Q40181756 | ||
| Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. | Q40213652 | ||
| Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. | Q40219504 | ||
| Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung | Q40283540 | ||
| Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models | Q40327891 | ||
| CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer | Q40333228 | ||
| Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. | Q40374208 | ||
| RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer | Q40390369 | ||
| Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses | Q40413612 | ||
| Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas | Q40416129 | ||
| Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme | Q40495113 | ||
| Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. | Q40538206 | ||
| Low-dose vaccinia virus-mediated cytokine gene therapy of glioma | Q40824587 | ||
| Vesicular stomatitis virus (VSV) therapy of tumors | Q40826109 | ||
| Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model | Q40835797 | ||
| Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma | Q40885287 | ||
| Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis | Q40906922 | ||
| Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer | Q40917912 | ||
| Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. | Q41148859 | ||
| Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant | Q41451279 | ||
| A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. | Q42639115 | ||
| Defective translational control facilitates vesicular stomatitis virus oncolysis | Q42831942 | ||
| Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas | Q43599287 | ||
| Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin | Q44110160 | ||
| Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid | Q44135421 | ||
| Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway | Q44432093 | ||
| Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 | ||
| Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma | Q44685850 | ||
| Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy | Q45180665 | ||
| Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. | Q45396446 | ||
| Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector | Q45419303 | ||
| Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme | Q45723594 | ||
| Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. | Q45739296 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. | Q45750082 | ||
| Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy | Q45753459 | ||
| Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy | Q45780980 | ||
| Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media | Q45858154 | ||
| Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy | Q45863191 | ||
| Newcastle disease virus selectively kills human tumor cells | Q45865340 | ||
| Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses | Q45871953 | ||
| HSV1716 persistence in primary human glioma cells in vitro | Q45888466 | ||
| Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity | Q48643464 | ||
| ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. | Q52291792 | ||
| A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Q52537791 | ||
| MTH-68/H oncolytic viral treatment in human high-grade gliomas. | Q53347956 | ||
| A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. | Q55467147 | ||
| Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. | Q55473726 | ||
| Therapeutic role of measles vaccine in Hodgkin's disease | Q72720992 | ||
| HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer | Q79124523 | ||
| Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma | Q81859838 | ||
| P433 | issue | 1 | |
| P921 | main subject | oncolytic virus | Q1560099 |
| P304 | page(s) | 1-13 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Recent patents on CNS drug discovery | Q26842296 |
| P1476 | title | Advances in oncolytic virus therapy for glioma | |
| P478 | volume | 4 |
| Q37622288 | "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment |
| Q38096940 | Advance in herpes simplex viruses for cancer therapy |
| Q96685704 | Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas |
| Q35210355 | Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model |
| Q38153777 | Clinical trials of viral therapy for malignant gliomas |
| Q34715771 | Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer |
| Q42155868 | Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model |
| Q33638847 | Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. |
| Q39420986 | Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells. |
| Q26996081 | Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy |
| Q35673628 | Gene therapy for malignant glioma |
| Q37787777 | HSV Recombinant Vectors for Gene Therapy |
| Q47141309 | Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma |
| Q45360866 | Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer |
| Q33895533 | Impact of tumor microenvironment on oncolytic viral therapy |
| Q59361065 | Integrating oncolytic viruses in combination cancer immunotherapy |
| Q35238250 | Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. |
| Q38253056 | Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme. |
| Q45341348 | Oncolytic Herpes Simplex Virus Glioblastoma Therapy is Potentiated by Tumor Necrosis Factor-α Inhibition |
| Q98894152 | Oncolytic virus therapy benefits from control theory |
| Q47124416 | Ral signaling pathway in health and cancer. |
| Q37818222 | Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma |
| Q37420576 | Strategies in gene therapy for glioblastoma. |
| Q30809060 | The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma |
| Q39537474 | The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo |
| Q36887446 | The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus |
| Q35522211 | Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients |
| Q41976320 | Viability reduction and Rac1 gene downregulation of heterogeneous ex-vivo glioma acute slice infected by the oncolytic Newcastle disease virus strain V4UPM |
Search more.